NASDAQ:NMRA
Neumora Therapeutics, Inc.
Neumora Therapeutics, Inc. reported net income of −$236.9M in fiscal 2025. The diluted share count rose 2.5%.Summary generated from Neumora Therapeutics, Inc.'s SEC filings. Latest annual report filed Mar 30, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−121.2%
Debt / equity0.52
Free cash flown/a
FCF marginn/a
Share count change+2.5%
Financials
| Item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | n/a | n/a | n/a | n/a |
| Operating income | −136 | −252 | −263 | −241 |
| Net income | −131 | −236 | −244 | −237 |
| Free cash flow | −115 | −163 | n/a | n/a |
Recent filings
- 4Insider transaction report
Aug 21, 2026 - 4Insider transaction report
Aug 21, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 14, 2026 - 8-KResults of operations and financial condition
Aug 14, 2026 - 8-KOther events
Jul 27, 2026 - 8-KEntry into a material agreement
Jun 15, 2026 - 8-KResults of a shareholder vote
May 29, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 7, 2026